Biolase's Days Sales Outstanding for the
three
months ended in Sep. 2024 was 35.2.
Biolase's Days Inventory for the
three
months ended in Sep. 2024 was 146.54.
Biolase's Days Payable for the
three
months ended in Sep. 2024 was 59.9.
Therefore, Biolase's Cash Conversion Cycle (CCC) for the
three
months ended in Sep. 2024 was 121.84.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Biolase Cash Conversion Cycle Related Terms
Biolase Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Biolase's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOLQ vs OPGN, AFIB, ABT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Biolase's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biolase Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Biolase's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Biolase's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biolase (BIOLQ) has a Cash Conversion Cycle of 121.84 as of Sep. 2024. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Biolase and its competitors.
Is Biolase's Cash Conversion Cycle too high?
Biolase's current Cash Conversion Cycle is 121.84. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Biolase's value of 121.84 is 22.4% below this industry median. Overall, Biolase has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biolase's Cash Conversion Cycle compare to OPGN and AFIB?
Biolase's Cash Conversion Cycle of 121.84 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Biolase's value of 121.84 is 22.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biolase's current Cash Conversion Cycle of 121.84 is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Biolase and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biolase's current Cash Conversion Cycle is 121.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biolase stock overvalued right now?
Biolase (BIOLQ) has a current Cash Conversion Cycle of 121.84. The current Cash Conversion Cycle is 121.84 and 22.4% below the Medical Devices & Instruments industry median of 156.96. Biolase's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Biolase (BIOLQ), the current Cash Conversion Cycle is 121.84 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
16GF Score
Get the complete analysis for BIOLQ
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOLQ has been successfully added to your 
